ADVERTISEMENTs
_page-0001.jpg)
Sonal Gupta named chief medical officer at CoRegen
Gupta will lead the company’s clinical and regulatory strategy as CoRegen prepares to move its steroid receptor coactivator (SRC-3) platform into clinical trials.
-
Pranavi Sharma - Sat, 02, Aug 2025
- 02:48 EDT
- 16
.jpg)
Sonal Gupta / LinkedIn
Indian-origin physician-scientist Sonal Gupta, M.D., Ph.D., has been appointed Chief Medical Officer at CoRegen, Inc., a biopharmaceutical company based in Houston developing therapies targeting solid tumors.
Gupta will lead the company’s clinical and regulatory strategy as CoRegen prepares to move its steroid receptor coactivator (SRC-3) platform into clinical trials. The platform aims to reprogram the SRC-3 gene to treat some of the most aggressive forms of cancer.
“Sonal Gupta joins CoRegen as we prepare to advance our SRC-3 platform into the clinic,” said Suneet Varma, Chairman of the Board.
He described her as a physician-scientist with experience in both clinical development and translational science.
“She brings a unique combination of clinical development expertise, translational science leadership, and deep regulatory experience across oncology and rare disease,” Varma said.
He added that her background in trial design, execution, and engagement with global regulatory bodies made her “an invaluable addition.”
Gupta said she was drawn to the company’s mission and scientific direction.
“CoRegen’s innovative approach to solid tumors and its commitment to improving patient outcomes align with my own passion for advancing medicine through collaboration and scientific excellence,” she said. “I look forward to working closely with the team to drive our clinical and regulatory strategies forward.”
Gupta brings nearly two decades of experience in the biotech and pharmaceutical sectors. She most recently served as Senior Vice President and Head of Clinical Development at AffyImmune Therapeutics, where she helped relaunch and expand clinical trials for autologous CAR T-cell therapies targeting non-small cell lung cancer and rare tumors.
Earlier, at AVROBIO, she was Head of Translational Medicine and oversaw gene therapy programs for Gaucher, Fabry, and Pompe diseases. She has also held senior roles at Rubius Therapeutics, CRISPR Therapeutics, and Selecta Biosciences, working on clinical development programs for sickle cell disease, thalassemia, and solid tumors.
Her areas of expertise include investigational new drug (IND) strategies, biomarker development, and global regulatory engagement.
Gupta earned her medical degree from Government Medical College in Surat, India, and completed a Ph.D. in cancer biology and immunology at the University of Bradford in the United Kingdom. She has authored multiple peer-reviewed publications and advised both industry and academic research programs.
Related
.jpg)
.JPG)
.JPG)
.jpeg)
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login